Nanosonics Ltd
Company Profile
Business description
Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics’ revenue is made up of capital sales of Trophon units, ongoing consumables sales, and service revenue. By June 2025, there were 37,000 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, over 50% in the US to single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
Contact
7-11 Talavera Road
Level 1 Building A
Macquarie Park
SydneyNSW2113
AUST: +61 280631600
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
30 June 2026
Employees
466
Nanosonics Ltd News & Analysis
stocks
ASX healthcare stocks shrug off new tariff threat
markets
Investing opportunities across these 3 asset classes
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,205.00 | 1.70 | -0.02% |
| CAC 40 | 8,157.29 | 43.59 | -0.53% |
| DAX 40 | 24,118.89 | 5.32 | -0.02% |
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% |
| FTSE 100 | 9,760.06 | 3.92 | 0.04% |
| HKSE | 26,050.08 | 232.61 | -0.89% |
| NASDAQ | 23,581.14 | 377.33 | -1.57% |
| Nikkei 225 | 52,211.69 | 886.08 | 1.73% |
| NZX 50 Index | 13,544.51 | 85.22 | 0.63% |
| S&P 500 | 6,822.34 | 68.25 | -0.99% |
| S&P/ASX 200 | 8,909.10 | 4.10 | -0.05% |
| SSE Composite Index | 3,961.62 | 25.28 | -0.63% |